Currently, there are 93.74M common shares owned by the public and among those 88.41M shares have been available to trade.
The company’s stock has a 5-day price change of 0.14% and -14.77% over the past three months. RARE shares are trading -15.24% year to date (YTD), with the 12-month market performance down to -12.12% lower. It has a 12-month low price of $29.59 and touched a high of $60.37 over the same period. RARE has an average intraday trading volume of 882.95K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.10%, -2.01%, and -21.93% respectively.
Institutional ownership of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) shares accounts for 95.30% of the company’s 93.74M shares outstanding.
It has a market capitalization of $3.37B and a beta (3y monthly) value of 0.27. The earnings-per-share (ttm) stands at -$5.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.56% over the week and 3.67% over the month.
Analysts forecast that Ultragenyx Pharmaceutical Inc (RARE) will achieve an EPS of -1.33 for the current quarter, -1.31 for the next quarter and -3.56 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.41 while analysts give the company a high EPS estimate of -1.41. Comparatively, EPS for the current quarter was -1.52 a year ago. Earnings per share for the fiscal year are expected to increase by 19.86%, and 35.27% over the next financial year. EPS should grow at an annualized rate of 83.56% over the next five years, compared to 2.45% over the past 5-year period.
Looking at the support for the RARE, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on June 06, 2024, with the firm’s price target at $56-$67. RBC Capital Mkts coverage for the Ultragenyx Pharmaceutical Inc (RARE) stock in a research note released on April 22, 2024 offered a Outperform rating with a price target of $77. Wells Fargo was of a view on December 08, 2023 that the stock is Overweight, while Credit Suisse gave the stock Outperform rating on June 14, 2023, issuing a price target of $96. Evercore ISI on their part issued Outperform rating on June 06, 2023.
